1
|
Laborde RJ, Ishimura ME, Abreu-Butin L, Nogueira CV, Grubaugh D, Cruz-Leal Y, Luzardo MC, Fernández A, Mesa C, Pazos F, Álvarez C, Alonso ME, Starnbach MN, Higgins DE, Fernández LE, Longo-Maugéri IM, Lanio ME. Sticholysins, pore-forming proteins from a marine anemone can induce maturation of dendritic cells through a TLR4 dependent-pathway. Mol Immunol 2021; 131:144-154. [PMID: 33422341 DOI: 10.1016/j.molimm.2020.12.032] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 11/30/2020] [Accepted: 12/24/2020] [Indexed: 02/06/2023]
Abstract
Sticholysins (Sts) I and II (StI and StII) are pore-forming proteins (PFPs), purified from the Caribbean Sea anemone Stichodactyla helianthus. StII encapsulated into liposomes induces a robust antigen-specific cytotoxic CD8+ T lymphocytes (CTL) response and in its free form the maturation of bone marrow-derived dendritic cells (BM-DCs). It is probable that the latter is partially supporting in part the immunomodulatory effect on the CTL response induced by StII-containing liposomes. In the present work, we demonstrate that the StII's ability of inducing maturation of BM-DCs is also shared by StI, an isoform of StII. Using heat-denatured Sts we observed a significant reduction in the up-regulation of maturation markers indicating that both PFP's ability to promote maturation of BM-DCs is dependent on their conformational characteristics. StII-mediated DC maturation was abrogated in BM-DCs from toll-like receptor (TLR) 4 and myeloid differentiation primary response gene 88 (MyD88)-knockout mice but not in cells from TLR2-knockout mice. Furthermore, the antigen-specific CTL response induced by StII-containing liposomes was reduced in TLR4-knockout mice. These results indicate that StII, and probably by extension StI, has the ability to induce maturation of DCs through a TLR4/MyD88-dependent pathway, and that this activation contributes to the CTL response generated by StII-containing liposomes.
Collapse
Affiliation(s)
- Rady J Laborde
- Laboratory of Toxins and Liposomes, Center for Protein Studies, Faculty of Biology, University of Havana (UH), Lab UH-CIM, Havana, 10400, Cuba.
| | - Mayari E Ishimura
- Discipline of Immunology, Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo (UNIFESP), 04023-062, São Paulo, Brazil.
| | - Lianne Abreu-Butin
- Discipline of Immunology, Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo (UNIFESP), 04023-062, São Paulo, Brazil
| | - Catarina V Nogueira
- Department of Microbiology and Immunobiology of Harvard Medical School, Harvard University, MA, USA.
| | - Daniel Grubaugh
- Department of Microbiology and Immunobiology of Harvard Medical School, Harvard University, MA, USA.
| | - Yoelys Cruz-Leal
- Laboratory of Toxins and Liposomes, Center for Protein Studies, Faculty of Biology, University of Havana (UH), Lab UH-CIM, Havana, 10400, Cuba.
| | - María C Luzardo
- Laboratory of Toxins and Liposomes, Center for Protein Studies, Faculty of Biology, University of Havana (UH), Lab UH-CIM, Havana, 10400, Cuba.
| | - Audry Fernández
- Immunobiology Division, Center of Molecular Immunology (CIM), Havana, 11600, Cuba.
| | - Circe Mesa
- Immunobiology Division, Center of Molecular Immunology (CIM), Havana, 11600, Cuba.
| | - Fabiola Pazos
- Laboratory of Toxins and Liposomes, Center for Protein Studies, Faculty of Biology, University of Havana (UH), Lab UH-CIM, Havana, 10400, Cuba.
| | - Carlos Álvarez
- Laboratory of Toxins and Liposomes, Center for Protein Studies, Faculty of Biology, University of Havana (UH), Lab UH-CIM, Havana, 10400, Cuba.
| | - María E Alonso
- Laboratory of Toxins and Liposomes, Center for Protein Studies, Faculty of Biology, University of Havana (UH), Lab UH-CIM, Havana, 10400, Cuba
| | - Michael N Starnbach
- Department of Microbiology and Immunobiology of Harvard Medical School, Harvard University, MA, USA.
| | - Darren E Higgins
- Department of Microbiology and Immunobiology of Harvard Medical School, Harvard University, MA, USA.
| | - Luis E Fernández
- Immunobiology Division, Center of Molecular Immunology (CIM), Havana, 11600, Cuba.
| | - Ieda M Longo-Maugéri
- Discipline of Immunology, Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo (UNIFESP), 04023-062, São Paulo, Brazil.
| | - María E Lanio
- Laboratory of Toxins and Liposomes, Center for Protein Studies, Faculty of Biology, University of Havana (UH), Lab UH-CIM, Havana, 10400, Cuba.
| |
Collapse
|
2
|
Granadillo M, Batte A, Alfonso AB, Blanco A, Urquiza D, Varas L, Soler D, Miyares M, Limonta M, Torrens I. Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate. Vaccine 2019; 37:3957-3960. [PMID: 31155419 DOI: 10.1016/j.vaccine.2019.05.060] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2018] [Revised: 05/14/2019] [Accepted: 05/21/2019] [Indexed: 12/24/2022]
Abstract
Cervical cancer is a global public health problem and human papillomavirus (HPV) 16 accounts for approximately 50% of cases worldwide. Although there are several types of HPV therapeutic vaccines in clinical research, there are currently not approved for use in humans. We developed the fusion protein LALF32-51-E7 (hereafter denominated CIGB550-E7) defined by a cell-penetrating peptide linked to an E7 mutein for the treatment of HPV16-associated tumors. We have demonstrated previously the benefit on antitumor response induced by the immunization with CIGB550-E7 admixed with very small size proteoliposomes (VSSP) adjuvant compared with the adjuvant-free immunization. In this study, we obtained a similar antitumor response in mice immunized with CIGB550-E7 admixed with the new adjuvant sVSSP that does not contain any animal-derived product. Also, the immunization with the above mentioned vaccine preparation induced a cell-mediated immune response. Our results are encouraging for the future clinical trials with the vaccine candidate CIGB550-E7+sVSSP.
Collapse
Affiliation(s)
- Milaid Granadillo
- Pharmaceutical Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba.
| | - Aileen Batte
- Pharmaceutical Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Alain B Alfonso
- Pharmaceutical Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Aracelys Blanco
- Direction of Preclinical Investigations and Animal Experimentation, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Dioslaida Urquiza
- Direction of Preclinical Investigations and Animal Experimentation, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Laura Varas
- Direction of Technological Development. Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Dayana Soler
- Direction of Technological Development. Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Maelys Miyares
- Direction of Technological Development. Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Miladys Limonta
- Direction of Technological Development. Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| | - Isis Torrens
- Pharmaceutical Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Cubanacán, Playa, Havana 10600, Cuba
| |
Collapse
|